RBC Capital lowered the firm’s price target on Danaher to $246 from $292 and keeps an Outperform rating on the shares as part of a broader research note on Life Science Tools names. The company has the most ‘bad business’ risk but also has the cleanest balance sheet, the analyst tells investors in a research note. As the biopharma market embarks on the next generation of therapeutics – including biosimilars, mRNA vaccines / therapies, and cell & gene therapy – Danaher is aligning itself to offer end-to-end solutions for customers, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DHR:
- Jonathan Milner urges Abcam shareholders to vote against proposed acquisition
- Abcam files scheme circular related to Danaher acquisition at $24 per share cash
- Danaher call volume above normal and directionally bullish
- Danaher price target lowered to $247 from $285 at Wells Fargo
- Here’s Why Danaher Stock (NYSE:DHR) Dropped Yesterday
Questions or Comments about the article? Write to editor@tipranks.com